Targeting KRAS-Mutant Solid Tumors With First-In-Class Oral SOS1 Bifunctional Degraders

Time: 3:00 pm
day: Day One Track A PM


  • Using our PRODEGY platform, Biotheryx have designed orally bioavailable bifunctional degraders of SOS1 – the guanine exchange factor catalysing the exchange of GDP to GTP in KRAS – as a mutation agnostic strategy to target KRAS mutant solid tumors.
  • Understand how the preclinical data shows rapid degradation of SOS1 in a Cereblon mediated proteasomal event and significant inhibition of a range of mutant KRAS tumor cell lines including those harbouring G12C, G12V, G12S and G13D mutations.
  • Showcasing how the SOS1 bifunctional degraders strongly synergize with inhibitors of KRAS, MEK and EGFR yielding a potent antitumor response relative to individual agents themselves.